Digital twins as global learning health and disease models for preventive and personalized medicine

Xinxiu Li, Joseph Loscalzo, A. K. M. Firoj Mahmud, Dina Mansour Aly, Andrey Rzhetsky, Marinka Žitnik, Mikael BensonGenome 2025 · DOI

TL;DR

This review proposes a framework for Medical Digital Twins (DTs)—virtual representations of biological processes—to move healthcare from reactive treatment to proactive, personalized prevention. By integrating multi-scale data ranging from population-wide disease trajectories to single-cell molecular interactions, DTs aim to solve the "ineffective medication" crisis by simulating patient-specific responses in silico before they happen in real life.

What Problem Does This Paper Address?

Modern medicine suffers from a "complexity gap." Most chronic diseases involve altered interactions among thousands of genes across billions of cells and multiple organs. Because disease progression is highly heterogeneous—influenced by a unique mix of genetics, environment, and lifestyle—standard "one-size-fits-all" treatments often fail or cause adverse side effects.

The authors argue that current diagnostic methods are too coarse to capture the decades-long "pre-symptomatic" phase of diseases. We need a system that can integrate massive, disparate data streams (electronic health records, multi-omics, environmental sensors) to predict individual health trajectories and prioritize the right therapeutic targets for the right patient at the right time.

Methods

The paper outlines a hierarchical approach to building and utilizing DTs:

  • Pop-DTs (Population-level): These use longitudinal data from millions of patients to identify "disease constellations" and temporal trajectories. The authors highlight the use of Natural Language Processing (NLP)-inspired word embeddings to map diseases into a continuous 20-dimensional "disease space," where diseases with similar etiologies cluster together.
  • Indi-DTs (Individual-level): These focus on high-resolution data, such as single-cell RNA sequencing (scRNA-seq), to build multicellular disease models (MCDMs).
  • Multilayer Network Analysis: To organize this data, the authors suggest Multilayer Disease Modules (MLDMs). These networks link different "layers" of reality—from SNPs and mRNA to symptoms and environmental factors—allowing researchers to see how a perturbation in one layer (like a toxic exposure) ripples through the others.
  • Advanced AI Architectures: The paper advocates for:
  • Self-supervised learning to leverage vast amounts of unlabeled medical data.
  • Geometric Deep Learning to model biological systems that naturally reside on non-Euclidean graphs (like protein-protein interaction networks).
  • Foundation Models that can be fine-tuned for specific clinical tasks via few-shot prompting.

Datasets

While this is a review paper, it cites several massive datasets used to validate these concepts:

  • Longitudinal Diagnostic Registry: Data from 200 million Americans used to identify ten major constellations of comorbid diseases.
  • US Environmental Quality Measures: Linked with health records of 480,000 individuals to study the interplay of genetics and environment in schizophrenia.
  • scRNA-seq Biopsies: Used in case studies of Crohn’s disease and arthritis to demonstrate how molecular constellations differ between patients with the same diagnosis.

Key Insights and Ideas

  • The "Whole-Body" Reality of Local Disease: A striking insight is that even "localized" diseases like arthritis involve molecular changes across multiple interconnected organs (lung, spleen, skin), even if those organs show no clinical symptoms. DTs must be multi-organ to be effective.
  • Explainability is Non-Negotiable: For DTs to be used in clinics, they cannot be "black boxes." The authors emphasize attribution maps (visualizing which data points drove a prediction) and visible neural networks (designed to mimic known biological pathways) to build clinician trust.
  • Learning Across Fields: The authors suggest that medical DTs should not exist in a vacuum but should interoperate with DTs from other fields, such as climatology and socioeconomics, to better understand the "exposome" (the sum of environmental exposures over a lifetime).

Key Results

The paper highlights several "early wins" for the DT approach:

  • Clinical Successes: Early applications include artificial lungs, the "artificial pancreas" for diabetes, and sex-specific whole-body models for infant metabolism.
  • Predictive Accuracy: In a study of Crohn’s disease, a multicellular DT correctly predicted which patients would respond to approved drugs and which would not, based on their specific molecular network topology.
  • Operational Efficiency: Siemens Healthineers and the Medical University of South Carolina used DTs to simulate hospital workflows, optimizing resource allocation (like ventilators and beds) during the COVID-19 pandemic.

Limitations and Future Work

Despite the promise, several "hurdles" remain:

  • Data Standardization: There is a critical lack of adopted standards for data generation, which hinders the ability of different DT systems to "talk" to each other (interoperability).
  • The Scaling Problem: Moving from a research setting to a global clinical standard requires addressing the "digital divide" to ensure equitable access for low-resource settings.
  • Ethics and Ownership: Who owns the data in a digital twin? The paper notes that protecting privacy while allowing for "federated data analysis" (where models learn from data without the data ever leaving its source) is a major regulatory challenge.
  • Dynamic Modeling: Capturing how molecular changes evolve in real-time across multiple biological scales remains a daunting computational task.

Summary updated

Abstract

Ineffective medication is a major healthcare problem causing significant patient suffering and economic costs. This issue stems from the complex nature of diseases, which involve altered interactions among thousands of genes across multiple cell types and organs. Disease progression can vary between patients and over time, influenced by genetic and environmental factors. To address this challenge, digital twins have emerged as a promising approach, which have led to international initiatives aiming at clinical implementations. Digital twins are virtual representations of health and disease processes that can integrate real-time data and simulations to predict, prevent, and personalize treatments. Early clinical applications of DTs have shown potential in areas like artificial organs, cancer, cardiology, and hospital workflow optimization. However, widespread implementation faces several challenges: (1) characterizing dynamic molecular changes across multiple biological scales; (2) developing computational methods to integrate data into DTs; (3) prioritizing disease mechanisms and therapeutic targets; (4) creating interoperable DT systems that can learn from each other; (5) designing user-friendly interfaces for patients and clinicians; (6) scaling DT technology globally for equitable healthcare access; (7) addressing ethical, regulatory, and financial considerations. Overcoming these hurdles could pave the way for more predictive, preventive, and personalized medicine, potentially transforming healthcare delivery and improving patient outcomes.
BibTeX
@inproceedings{li2025digital,
  author = {Xinxiu Li and Joseph Loscalzo and A. K. M. Firoj Mahmud and Dina Mansour Aly and Andrey Rzhetsky and Marinka Žitnik and Mikael Benson},
  title = {{Digital twins as global learning health and disease models for preventive and personalized medicine}},
  booktitle = {Genome},
  year = {2025},
  doi = {10.1186/s13073-025-01435-7},
}
Figure